Notably, the authors demonstrated that either amplification of ErbB2 or increased levels of the ErbB3/ErbB4 ligand heregulin led to de novo or acquired cetuximab resistance (18), and Ruan et al achieved similar results in a breast cancer study (19). Here, ERBB3 is linked to breast carcinoma.